<DOC>
	<DOCNO>NCT01581749</DOCNO>
	<brief_summary>The primary safety purpose study estimate rate immediate long-term high grade ( grade 3-5 ) gastrointestinal genitourinary side effect five year TrueBeam stereotactic body radiotherapy low-risk intermediate-risk prostate cancer patient . The primary efficacy purpose compare 5 year biochemical disease free survival rate TrueBeam 5 year biochemical disease free survival rate dose-escalated external beam radiation therapy .</brief_summary>
	<brief_title>Evaluation Truebeam Low-Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>The prescribed PTV dose 36.25Gy shall give 5 fraction use Truebeam STx . At one week treatment , toxicity AUA score evaluate . At 1 month follow treatment , patient assess acute toxicity , fill AUA form , SF-12 , EPIC-26 , SHIM Utilization Sexual Rx/Devices . At 3 , 6 , 12 , 18 , 24 month interval ( every 6 month thereafter , year 5 , annually year 10 , investigator opt continue past year 5 ) , patient see evaluate , include history , physical exam , ECOG performance status , PSA , toxicity evaluation , AUA score . In addition , 6 month , 12 month annually thereafter , SF-12 , EPIC-26 , SHIM Utilization Sexual Medications/Devices administer . Examination study may do outside facility . A prostate biopsy perform time biochemical local clinical failure , encourage 2 year follow treatment time distant failure .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histologically proven prostate adenocarcinoma within 1 year enrollment Low risk : Gleason &lt; or=6 &amp; PSA &lt; or=10 &amp; Clinical Stage T1bT2a , Nx N0 , Mx M0 Intermediate risk : Gleason &lt; or=6 &amp; PSA &lt; or=10 &amp; Clinical Stage T2b OR Gleason=7 &amp; PSA &lt; or=10 &amp; Clinical Stage T1bT2b OR Gleason &lt; or=6 &amp; PSA &gt; 10 &amp; &lt; =20 &amp; Clinical Stage T1b T2b , Nx NO , Mx M0 ECOG Performance Status 01 No prior prostate radiation definitive therapy implant hardware material would prohibit treatment plan delivery chemotherapy malignancy within previous 5 year history invasive malignancy ( prostate cancer , basal squamous skin cancer ) within prior 5 year hormone ablation 2 month prior treatment treatment</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>low risk prostate cancer</keyword>
	<keyword>intermediate risk prostate cancer</keyword>
	<keyword>stereotactic radiosurgery</keyword>
</DOC>